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Intravitreal ranibizumab therapy is widely used in treatment of subfoveal choroidal neovascularisation (CNV) in age-related
macular degeneration. We wanted to study the eﬀect of intravitreal ranibizumab therapy in peripapillary CNV. A prospective
recording of treatment outcomes in twelve eyes (12 patients) with peripapillary CNV with intravitreal injections of ranibizumab
was performed. The patients received a series of 3 injections 4–6 weeks apart, and then a new ophthalmic examination was made
including OCT and further therapy was given if the peripapillary CNV was still active. Nine patients had idiopathic peripapillary
CNV, and in 3 patients it was associated to age-related macular degeneration. Followup had to be at least 6 months. The mean
follow-up time was 15.9 (range 9–27) months and the mean number of injections 6.2 (3–10). In 10 patients treatment had resulted
in an inactivation of the peripapillary CNV, but 3 of them had reactivation, while 2 patients had no inactivation. Currently, 5
patients are continuous to receive treatment. VA improved in 10 patients. Intravitreal ranibizumab therapy appears to be eﬀective
inpatientswithperipapillaryCNV,butinsomecasesthereisrepeatedreactivationorcontinuousactivityoftheperipapillaryCNV.
1.Introduction
The use of antivascular endothelial growth factor (anti-
VEGF) agents for the treatment of retinal diseases is con-
stantly increasing. Anti-VEGF was primarily introduced for
the treatment of age-related macular degeneration (AMD)
complicated with a sub- or juxtafoveal choroidal neovas-
cularisation, but its use is now expanding to retinal vein
occlusions and diabetic macular edema [1–3].
Peripapillary CNV is rare. Several conditions can cause
peripapillary CNV including AMD (the most common
cause, 45.2% of the cases), idiopathic (39.1%), multifocal
choroiditis (4.3%), angioid streaks (2.6%), histoplasmosis
(1.7%), choroidal osteoma (1.7%), optic disc drusen (0.9%),
and congenital disc anomaly (0.9%) and has been reported
in sarcoid [4]. No randomised or large study has evaluated
the eﬃcacy of anti-VEGF on peripapillary CNV hence
standard care for peripapillary CNV remains argon laser
photocoagulation or photodynamic therapy [5, 6]. However,
sinceanti-VEGFiseﬀectiveintreatingCNV,itseemsrelevant
to treat peripapillary CNV with anti-VEGF.
Information regarding the eﬃcacy of anti-VEGF on
peripapillary CNV is based on case reports and small case
series [7–12]. Overall the results suggest a possible beneﬁcial
eﬀect of anti-VEGF on peripapillary CNV, but questions
remain regarding the long-term beneﬁcial eﬀect of the
treatment, since continuous visual decline, and CNV activity
despite treatment has been reported in some patients [7, 12].
The purpose of this study was to evaluate the eﬃcacy of
ranibizumab in patients with peripapillary CNV.
2. Methods
Twelve eyes (12 patients) were included in this study. At
baseline all patients underwent an ophthalmic examina-
tion including a dilated fundus examination, best-corrected
visual acuity (VA) using the early treatment of diabetic
retinopathy study (ETDRS) chart, spectral domain optical
coherence tomography (SD-OCT) imaging using Heidelberg
HRA-Spectralis system (Heidelberg Engineering, Heidel-
berg, Germany) and ﬂuorescein angiography (FA) as well as2 Journal of Ophthalmology
Table 1: Patient characteristics and treatment results. (F: female; M: male). (Central retinal thickness).
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1 F 80 Idiopathic 77 78 10 302 235 22 Continuous
treatment
2 M 74 Idiopathic 65 76 9 291 211 21 Continuous
treatment
3 F 70 Idiopathic 59 83 3 461 210 14 Inactive
4 F 81 AMD 65 45 9 486 140 27 Continuous
treatment
5 F 87 Idiopathic 70 85 3 274 245 18 Inactive
6 F 76 Idiopathic 35 46 3 400 292 23 Inactive
7 F 70 Idiopathic 85 90 9 280 280 17 Inactive
8 F 81 Idiopathic 65 70 6 615 543 9 Continuous
treatment
9 M 76 AMD 65 73 6 348 280 15 Inactive
10 M 76 AMD 28 32 5 500 384 9 Inactive
11 M 28 Idiopathic 26 47 6 350 322 9 Inactive
12 M 81 Idiopathic 72 63 5 307 250 9 Continuous
treatment
indocyanine green (ICG) angiography to rule out polypoidal
vasculopathy was performed. The patients were initially
assigned to 3 intravitreal injections of 0.5mg ranibizumab
4–6 weeks apart.
Approximately, 1 month after the 3rd injection the
patients returned for a clinical reevaluation including VA,
SD-OCT, and dilated fundus examination. The OCT was
both done through the fovea and the optic nerve. Based on
signs of activity (intra- or subretinal ﬂuid or retinal haemor-
rhages) it was decided whether to continue treatment using a
variable dosing regimen—1 to 3 injections—or to reevaluate
thepatientagainevery4–6weeks.Thereevaluationconsisted
of repeated VA, SD-OCT and dilated fundus examinations.
We did not use FA to evaluate reactivation.
Informed consent was obtained from all participants
and they all agreed to the oﬀ-label nature of the treatment.
None of the patients had received any other treatment for
peripapillary CNV.
3. Results
Patient characteristics and treatment results are shown in
Table 1 and Figure 1. All patients were Caucasian, with a
mean age of 73 years (range: 28–87), 7 females and 5 males.
The mean length of followup was 15.9 months (range:
9–27). The mean number of injections with intravitreal
ranibizumab was 6.2 (range: 3–10). In patients without
obvious signs of drusen and/or changes in the RPE the
CNV was categorized as idiopathic. Nine eyes had idiopathic
peripapillary CNV and 3 eyes had peripapillary CNV as part
of AMD (Figure 2). All patients presented with subfoveal
ﬂuid causing a decrease of vision. The mean visual acuity
at baseline was 59 letters (range: 26–85) and had signiﬁ-
cantly improved to 66 letters (range: 32–90) after treatment
(P = 0.002, paired samples t-test). Ten out of 12 patients





















Figure 1: Changes in visual acuity after treatment.
experienced an improvement in VA after treatment while
vision declined in 2 patients.
Inactivation after the initial treatment regime with three
injections was obtained in 5 patients, and of them 2
patients experienced reactivation after 8 and 16 months,
respectively. In 5 other patients inactivation was obtained
after 5–10 injections, of them 1 patient had reactivation
after 18 months. Two patients had no inactivation and do
receive continuous treatment. Currently, 7 patients show
no sign of activity of the CNV, while 5 patients are still
receiving treatment at the time of followup. In total 10
out of 12 patients experienced inactivation at some point
of followup, and of them 3 patients had reactivation. The
central retinal thickness (CRT) decreased in all but 1 patientsJournal of Ophthalmology 3
(a)
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Figure 2: An example of fundus photography showing peripapil-
laryCNVbeforeandaftertreatmentinapatientwithAMD(patient
4).
(Table 1). All 3 patients with AMD had inactivation after 3,
5, and 6 injections, respectively. The patient with 3 injections
had reactivation after 16 months. Of the 9 patients with
idiopathic CNV, inactivation was achieved in 7 patients,
of them 2 had reactivation, and 2 others did not obtain
inactivation and do still receive treatment.
4. Discussion
Peripapillary CNV is rare and treatment studies of this
condition consist primarily of short case reports and case
seriestreatingperipapillaryCNVwitheitherbevacizumabor
ranibizumab.
Four reports on the eﬀect of bevacizumab have been
published [7–9, 11]. Two are small case series, 6 eyes and
4 eyes, respectively, and two are case reports adding up to
12 eyes in total with variable aetiologies to the peripapil-
lary CNV [7–9, 11]. Follow-up ranges from 3 months to
mean followup of 13 months. All studies report an initial
favourable response to treatment, but in the study with the
longest follow-up, inactivity was obtained in ﬁve of six eyes,
and one eye did not respond to treatment [7]. These ﬁndings
correspond to our ﬁndings where 10 out of 12 patients had
inactivation. Even though the ﬁndings are similar, there are
severaldiﬀerencesinourstudyandthestudyofFigueroaand
coworkers the patients were treated with bevacizumab, mean
age was 67.8 years, and mean VA at baseline was 44 letters,
and 2 patients had earlier been treated with surgical removal
of the neovascular membrane [7]. There is also diﬀerence in
thelengthoffollow-upintheirstudycomparedtoours,since
they had a mean followup of 13 months (range 6–16), and 2
of our patients had reactivation after 16 and 18 months of
followup.
Only two papers have reported on the eﬃcacy of
ranibizumab in peripapillary CNV [10, 12]. One is a case
series of seven eyes (6 patients) and one is a case report.
The case series studied patients with paripapillary CNV of
various aetiologies (4 angioid streaks, 2 idiopathic, 1 as part
of AMD) with a mean followup of 12 months. Ranibizumab
was successful in improving VA and resolution of subfoveal
ﬂuid was accomplished. [10] The case report studied one
patient with sarcoidosis, uveitis, and peripapilliary CNV and
after 12 months of followup there were still signs of activity
[12].
Even though peripapillary CNV in some instances can
be watched because of the asymptomatic nature, treatment
should be considered when the fovea is threatened. Treat-
ment of peripapillary CNV has recently been reviewed, and
generally there is lack of evidence concerning the ideal
treatment strategy in patients with peripapillary CNV, even
though the theoretical rationale favours treatment with anti-
VEGF [13].
In our study, we ﬁnd a tendency towards eﬃcacy of
ranibizumab in the treatment of peripapillary CNV. How-
ever, complete inactivation of the CNV was only obtained
in 7 of 12 patients (58%) at the end of followup. In the
majority of patients, VA improves and the CRT decreases
on OCT. Even though our study has a limited number of
patients it is still the largest number of cases and the longest
followup so far reporting on the eﬃcacy of ranibizumab in
peripapillary CNV. Our ﬁndings suggest that ranibizumab is
a feasible solution for the treatment of peripaillary CNV, but
reactivation and lack of inactivation resulting in a need for
continuous treatment are common.
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